Senores Pharmaceuticals

Senores Pharmaceuticals

776.60
+11.55
(1.51%)
hide
Key Fundamentals
Add Ratio
Market Cap
3,523.30 Cr
EPS
16.12
PE Ratio
41.81
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
832.00
52 Week Low
435.25
PB Ratio
4.40
Debt to Equity
0.58
Analyst Rating and Forecast
- By Refinitiv from4 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
neutral
Senores Pharmaceuticals Limited submitted its monitoring agency report for the quarter ended September 30, 2025, showing utilization of Rs. 309.07 crore out of Rs. 500 crore raised through its IPO. CARE Ratings Limited, the monitoring agency, reported no deviation from stated objectives. The company completed repayment of certain borrowings totaling Rs. 93.30 crore during the quarter. Key utilizations included Rs. 3.67 crore for Atlanta facility setup, Rs. 39.61 crore for working capital requirements, and Rs. 45.36 crore for subsidiary investments. The company maintains Rs. 190.93 crore in unutilized proceeds, primarily deployed in fixed deposits with HDFC Bank and ICICI Bank. Some delays were noted in implementation timelines, with management committee approvals granted for extensions. The report was reviewed by the Audit Committee and approved by the Board on November 6, 2025.
positive
Senores Pharmaceuticals Limited announced its quarterly results for the quarter and half year ended September 30, 2025. The company reported consolidated revenue of Rs. 162 crores for Q2, representing 61% year-on-year growth, with profit after tax of Rs. 30 crores showing 131% year-on-year increase. For the half year, consolidated revenue reached Rs. 300 crores with 66% growth and profit after tax of Rs. 51 crores with 114% growth. The regulated markets segment delivered 87% year-on-year growth in Q2, while the branded generics business witnessed significant growth with revenues growing more than tenfold year-on-year. The company generated Rs. 31.4 crores in operating cash flow for the half year. Additionally, the board approved the appointment of Mr. Manohar Lalge as President-Research and Development and categorized him as Senior Management Personnel effective November 6, 2025. Mr. Lalge brings over 25 years of experience in pharmaceutical formulation development.
positive
Senores Pharmaceuticals reported quarterly revenue of 1.6 billion rupees compared to 1 billion rupees in the same period last year, representing a year-over-year increase of 60%.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,732.10
#1 4,11,749.90
39.63
#1 54,729.00
9.71
#1 10,980
2.89
66.26
6,520.00
1,73,603.20
69.64
9,712.00
18.67
2,191
35.10
50.59
3,824.60
1,29,482.50
60.46
11,539.40
6.99
1,911
30.46
70.50
1,519.30
1,22,366.70
22.59
28,409.50
7.12
5,291
3.71
44.46
1,229.60
1,01,113.50
#1 17.88
33,741.20
16.73
5,725
-0.38
47.35
951.40
94,475.30
19.03
23,511.00
18.55
4,615
34.60
39.39
2,270.00
91,653.00
52.89
12,744.20
#1 20.90
2,007
-21.05
32.59
2,033.90
90,250.10
21.39
22,909.50
13.74
3,306
#1 72.75
62.84
5,767.50
68,110.20
29.54
13,458.30
3.70
2,216
21.39
70.49
1,183.60
67,849.20
20.35
32,345.60
9.43
3,484
3.81
67.18
Growth Rate
Revenue Growth
92.13 %
Net Income Growth
78.29 %
Cash Flow Change
-78.68 %
ROE
-49.15 %
ROCE
1.63 %
EBITDA Margin (Avg.)
27.75 %

Quarterly Financial Results

Quarterly Financials
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
80
104
80
100
108
117
134
159
Expenses
64
80
59
77
77
95
104
112
EBITDA
16
24
21
23
31
22
30
47
Operating Profit %
19 %
22 %
26 %
21 %
25 %
10 %
20 %
27 %
Depreciation
3
4
4
4
4
5
6
8
Interest
3
3
5
5
6
5
5
6
Profit Before Tax
10
18
14
16
21
21
27
41
Tax
3
3
3
3
4
3
5
11
Net Profit
7
14
11
13
16
18
21
30
EPS in ₹
4.01
8.03
3.39
3.92
5.04
3.81
4.60
6.54

Balance Sheet

Balance Sheet
2022
2023
2024
2025
Total Assets
59
131
622
1,227
Fixed Assets
7
27
235
301
Current Assets
27
51
251
722
Capital Work in Progress
8
35
97
173
Investments
15
17
0
0
Other Assets
29
53
289
754
Total Liabilities
59
131
622
1,227
Current Liabilities
10
52
248
241
Non Current Liabilities
13
34
143
174
Total Equity
37
46
232
812
Reserve & Surplus
28
36
174
740
Share Capital
9
10
31
46

Cash Flow

Cash Flow
2022
2023
2024
2025
Net Cash Flow
2
-3
8
98
Investing Activities
-24
-48
-54
-430
Operating Activities
-10
-1
-26
-46
Financing Activities
37
46
87
573

Share Holding

% Holding
Jul 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
66.66 %
45.76 %
45.76 %
45.77 %
45.78 %
45.80 %
FIIs
0.00 %
5.51 %
4.25 %
4.17 %
3.67 %
4.28 %
DIIs
0.00 %
18.61 %
11.78 %
9.65 %
9.51 %
8.61 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
27.88 %
28.71 %
31.43 %
31.44 %
31.09 %
Others
33.34 %
2.23 %
9.49 %
8.97 %
9.60 %
10.22 %
No of Share Holders
177
43,707
43,707
37,653
36,389
34,917

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
23 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
23 Jan 2025 530.80 498.50
15 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
15 May 2025 483.75 541.05
23 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
23 Jul 2025 617.55 616.35
18 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
18 Sept 2025 717.85 689.25
06 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
06 Nov 2025 783.35 766.75

Announcements

Announcement under Regulation 30 (LODR)-Newspaper Publication5 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome6 days ago
Announcement under Regulation 30 (LODR)-Monitoring Agency Report6 days ago
Announcement under Regulation 30 (LODR)-Change in Management6 days ago
Announcement under Regulation 30 (LODR)-Investor Presentation6 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release6 days ago
Results For Quarter And Half Year Ended September 30 20256 days ago
Board Meeting Outcome for Outcome Of The Board Meeting Held On November 06 20256 days ago
Announcement under Regulation 30 (LODR)-Acquisition7 days ago
Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 20157 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 29, 2025
Board Meeting Intimation for Considering And Approving The Un-Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30 2025 And To Transact Other Business MattersOct 29, 2025
Intimation For Change In Email Address Of MUFG Intime India Private Limited Registrar And Share Transfer Agent (RTA) Of The CompanyOct 08, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 08, 2025
Closure of Trading WindowSep 26, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 18, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 18, 2025
Intimation Under Regulation 30(6) Of SEBI (LODR) Regulations 2015.Sep 18, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionSep 12, 2025
Reg. 34 (1) Annual Report.Sep 05, 2025
Re-Scheduling Of The Analyst / Institutional Investor Meetings Under The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 02, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 01, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 01, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 28, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 28, 2025
Notice Of Eighth (8Th) Annual General Meeting To Be Held On September 18 2025Aug 26, 2025
Reg. 34 (1) Annual Report.Aug 26, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 25, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 25, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 25, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 25, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 25, 2025
Cancellation Of Analyst / Institutional Investor Meetings Under The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015Aug 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 13, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 05, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJul 30, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 30, 2025
Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 28, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 24, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 24, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJul 23, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 23, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportJul 23, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJul 23, 2025
Financial Results For Quarter Ended On June 30 2025Jul 23, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Held On July 23 2025Jul 23, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 19, 2025
Board Meeting Intimation for Considering And Approving The Un-Audited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 2025And To Transact Other Business MattersJul 17, 2025
Resubmission Of Intimation For Issuance Of The Corporate Guarantee Dated July 10 2025Jul 14, 2025

Mutual Fund Holdings

Technical Indicators

RSI(14)
Neutral
52.52
ATR(14)
Less Volatile
27.86
STOCH(9,6)
Neutral
52.71
STOCH RSI(14)
Neutral
40.83
MACD(12,26)
Bullish
0.48
ADX(14)
Strong Trend
35.24
UO(9)
Bearish
42.86
ROC(12)
Uptrend And Accelerating
2.64
WillR(14)
Neutral
-69.74